Publications by authors named "Taro Semba"

Claim this Profile
P
Phase 1b/2 study of the liposomal formulation of eribulin (E7389-LF) in combination with nivolumab: Results from the phase 2 esophageal cancer cohort.
Takashi Oshima, Sachiko Yamamoto, Hisato Kawakami, Tomoki Makino, Akihito Kawazoe, Taro Semba

BJC Rep· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort.
Akihito Kawazoe, Noboru Yamamoto, Naotoshi Sugimoto, Hisato Kawakami, Takashi Oshima, Taro Semba

Clin Cancer Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amelioration of Tumor-promoting Microenvironment via Vascular Remodeling and CAF Suppression Using E7130: Biomarker Analysis by Multimodal Imaging Modalities.
Ken Ito, Masayuki Yamaguchi, Taro Semba, Kimiyo Tabata, Moe Tamura

Mol Cancer Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort.
Makoto Nishio, Shuji Murakami, Hisato Kawakami, Kyoichi Okishio, Motohiro Tamiya, Taro Semba

Cancer Res Commun· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human study of E7130 (a tumor microenvironment-ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose-escalation part.
Toshihiko Doi, Nobuaki Matsubara, Yoichi Naito, Yasutoshi Kuboki, Kenichi Harano, Taro Semba

Cancer· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib.
Hanae Ida, Toshio Shimizu, Makoto Nishino, Yoshiaki Nakamura, Shu Yazaki, Taro Semba

Cancer Res Commun· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti-PD-1 Antibody.
Yuki Niwa, Keito Adachi, Kimiyo Tabata, Ryoga Ishida, Koichiro Hotta, Taro Semba

Mol Cancer Ther· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort.
Kohei Shitara, Motohiro Hirao, Satoru Iwasa, Takashi Oshima, Yoshito Komatsu, Taro Semba

Clin Cancer Res· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Cluster Analysis Method for Quantitative Dynamic Contrast-Enhanced MRI Assessing Tumor Heterogeneity Induced by a Tumor-Microenvironmental Ameliorator (E7130) Treatment to a Breast Cancer Mouse Model.
Kazuyuki Makihara, Masayuki Yamaguchi, Ken Ito, Kazuya Sakaguchi, Yusaku Hori, Taro Semba

J Magn Reson Imaging· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort.
Norikazu Masuda, Makiko Ono, Toru Mukohara, Hiroyuki Yasojima, Tatsunori Shimoi, Taro Semba

Eur J Cancer· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors.
Jun Sato, Toshio Shimizu, Takafumi Koyama, Satoru Iwasa, Akihiko Shimomura, Taro Semba

Clin Cancer Res· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling.
Kazuhiko Yamada, Yusaku Hori, Satoshi Inoue, Yuji Yamamoto, Kentaro Iso, Taro Semba

Cancer Res· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models.
Yuki Niwa, Makoto Asano, Takayuki Nakagawa, Damien France, Taro Semba

Anticancer Res· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Clinical benefit of eribulin (Halaven) in the treatment of advanced soft tissue sarcoma patients and the novel anti-tumor mechanisms].
Noriyuki Koyama, Shigeru Taniguchi, Kotaro Kodama, Osamu Tohyama, Hiroki Hasegawa, Taro Semba

Nihon Yakurigaku Zasshi· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models.
Yasuhiro Funahashi, Kiyoshi Okamoto, Yusuke Adachi, Taro Semba, Mai Uesugi

Cancer Sci· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage.
Yuji Yamamoto, Junji Matsui, Tomohiro Matsushima, Hiroshi Obaishi, Kazuki Miyazaki, Taro Semba

Vasc Cell· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models.
Ken Ito, Taro Semba, Toshimitsu Uenaka, Toshiaki Wakabayashi, Makoto Asada

Cancer Sci· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor.
Takayuki Nakagawa, Tomohiro Matsushima, Satoshi Kawano, Youya Nakazawa, Yu Kato, Taro Semba

Cancer Sci· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Current status of combination therapies of angiogenesis inhibitors: vascular normalization activity of a novel angiogenesis inhibitor E7820].
Taro Semba

Nihon Yakurigaku Zasshi· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An angiogenesis inhibitor E7820 shows broad-spectrum tumor growth inhibition in a xenograft model: possible value of integrin alpha2 on platelets as a biological marker.
Taro Semba, Yasuhiro Funahashi, Naoto Ono, Yuji Yamamoto, Naoko Hata Sugi

Clin Cancer Res· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium.
Yasuhiro Funahashi, Naoko Hata Sugi, Taro Semba, Yuji Yamamoto, Shinichi Hamaoka

Cancer Res· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis